Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 1, 2004, Pages 231-234

  Abbate, Francesco ^a   Winum, Jean Yves ^b   Potter, Barry V L ^c   Casini, Angela ^a   Montero, Jean Louis ^b   Scozzafava, Andrea ^a   Supuran, Claudiu T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIV MONTPELLIER   (France)

^c University of Bath   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE INHIBITOR; ENZYME INHIBITOR; ESTRONE 3 O SULFAMATE; PHENYLALANINE; PROLINE; STERYL SULFATASE INHIBITOR; UNCLASSIFIED DRUG; VALINE; ZINC;

ARTICLE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVE SITE; HYDROPHOBICITY; X RAY CRYSTALLOGRAPHY;

EID: 0346252639     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.09.064     Document Type: Article

References (38)

1. (a) Winum J.-Y., Vullo D., Casini A., Montero J.-L., Scozzafava A., Supuran C.T. J. Med. Chem. 46:2003;2197
2. (b) Vicker N., Ho Y., Robinson J., Woo L.W.L., Purohit A., Reed M.J., Potter B.V.L. Bioorg. Med. Chem. Lett. 13:2003;863
3. (c) Ho Y.T., Purohit A., Vicker N., Newman S.P., Robinson J.J., Leese M.P., Ganeshapillai D., Woo L.W.L., Potter B.V.L., Reed M.J. Biochem. Biophys. Res. Commun. 305:2003;909.
4. (a) Supuran C.T., Scozzafava A., Casini A. Med. Res. Rev. 23:2003;146
5. (b) Supuran C.T., Scozzafava A. Curr. Med. Chem. Imm., Endoc. Metab. Agents. 1:2001;61.
6. (a) Supuran C.T., Scozzafava A. Exp. Opin. Ther. Pat. 12:2002;217
7. (b) Supuran C.T., Scozzafava A. Exp. Opin. Ther. Pat. 10:2000;575.
8. (a) Smith H.J., Nicholls P.J., Simons C., Le Lain R. Exp. Opin. Ther. Pat. 11:2001;789
9. (b) Ahmed S., Owen C.P., James K., Sampson L., Patel C.K. Curr. Med. Chem. 9:2002;263
10. (c) Woo L.W.L., Howarth N.M., Purohit A., Hejaz H.A.M., Reed M.J., Potter B.V.L. J. Med. Chem. 41:1998;1068.
11. (a) Woo L.W.L., Purohit A., Malini B., Reed M.J., Potter B.V.L. Chem. Biol. 7:2000;773
12. (b) Poirier D., Ciobanu L.C., Maltais R. Exp. Opin. Ther. Pat. 9:1999;1083
13. (c) Ciobanu L.C., Luu-The V., Poirier D. J. Steroid Biochem. Mol. Biol. 80:2002;339
14. (d) Malini B., Purohit A., Ganeshapillai D., Woo L.W.L., Potter B.V.L., Reed M.J. J. Steroid Biochem. Mol. Biol. 75:2000;253.
15. Scozzafava A., Owa T., Mastrolorenzo A., Supuran C.T. Curr. Med. Chem. 10:2003;925.
16. Casini A., Scozzafava A., Mastrolorenzo A., Supuran C.T. Curr. Cancer Drug Targets. 2:2002;55.
17. Chegwidden W.R., Spencer I.M., Supuran C.T. The roles of carbonic anhydrase isozymes in cancer. Xue G., Xue Y., Xu Z., Holmes R., Hammond G.L., Lim H.A. Gene Families: Studies of DNA, RNA, Enzymes and Proteins. 2001;157 World Scientific, Singapore.
18. (a) Pastorek J., Pastorekova S., Callebaut I., Mornon J.P., Zelnik V., Opavsky R., Zatovicova M., Liao S., Portetelle D., Stanbridge E.J., Zavada J., Burny A., Kettmann R. Oncogene. 9:1994;2877
19. (b) Wykoff C.C., Beasley N., Watson P.H., Turner K.J., Pastorek J., Sibtain A., Wilson G.D., Turley H., Talks K.L., Maxwell P.H., Pugh C.W., Ratcliffe P., Harris A.L. Cancer Res. 60:2000;7075
20. (c) Beasley N., Wykoff C.C., Watson P.H., Leek R., Turley H., Gatter K., Pastorek J., Cox G.J., Ratcliffe P.J., Harris A.L. Cancer Res. 61:2001;5262.
21. (a) Supuran C.T. Exp. Opin. Investig. Drugs. 12:2003;283
22. (b) Supuran C.T., Briganti F., Tilli S., Chegwidden W.R., Scozzafava A. Bioorg. Med. Chem. 9:2001;703.
23. (a) Ilies M.A., Vullo D., Pastorek J., Scozzafava A., Ilies M., Caproiu M.T., Pastorekova S., Supuran C.T. J. Med. Chem. 46:2003;2187
24. (b) Vullo D., Franchi M., Gallori E., Pastorek J., Scozzafava A., Pastorekova S., Supuran C.T. Bioorg. Med. Chem. Lett. 13:2003;1005
25. (c) Franchi M., Vullo D., Gallori E., Pastorek J., Russo A., Scozzafava A., Pastorekova S., Supuran C.T. J. Enz. Inhib. Med. Chem. 18:2003;333.
26. Suitters A.J., Shaw S., Wales M.R., Porter J.P., Leonard J., Woodger R., Brand H., Bodmer M., Foulkes R. Immunology. 91:1997;314.
27. (a) Abbate F., Supuran C.T., Scozzafava A., Orioli P., Stubbs M., Klebe G. J. Med. Chem. 45:2002;3583
28. (b) Casini A., Antel J., Abbate F., Scozzafava A., David S., Waldeck H., Schäfer S., Supuran C.T. Bioorg. Med. Chem. Lett. 13:2003;841.
29. Leslie, A.G.W. Joint CCP4+ESF-EAMCB Newsletter on Protein Crystallography, No. 26, 1992.
30. Sheldrick G.M. SHELX97. 1997;University of Göttingen, Göttingen, Germany.
31. Jones T.A., Cowan S.W., Kjeldgaard M. Acta Crystallogr. A47:1991;110.
32. c were then calculated, where Fc and phases were obtained from the native hCA II model from which all the water molecules have been omitted. The difference Fourier maps after the first refinement cycle, before the assignment of water molecules, already showed clear evidence for the presence of the inhibitor molecule, whose occupancy was at the end of the refinement of 100%. The hCA II-EMATE complex data were collected at Elettra Synchrotron in Trieste (Italy) on a 165 mm MarCCD detector at 100 mm from the crystal, using radiation of 1.00 Å wavelength and about 15-s exposure and 110 K.
33. Hakansson K., Carlsson M., Svensson L.A., Liljas A. J. Mol. Biol. 227:1992;1192.
34. (a) Kim C.Y., Chandra P.P., Jain A., Christianson D.W. J. Am. Chem. Soc. 123:2001;9620
35. (b) Gruneberg S., Wendt B., Klebe G. Angew. Chem., Int. Ed. 40:2001;389.
36. Abbate F., Casini A., Scozzafava A., Supuran C.T. J. Enz. Inhib. Med. Chem. 18:2003;303.
37. Casini A., Abbate F., Scozzafava A., Supuran C.T. Bioorg. Med. Chem. Lett. 13:2003;2759.
38. The coordinates of the hCA II-EMATE adduct are available immediately from claudiu.supuran@unifi.it .